Tri Asih Imro'ati, - and Mochammad Thaha, - and Aditiawardana, - and Widodo, - and Pranawa, - and Chandra Irwanadi, - and widodo, - (2018) Comparison of high-sensitivity C-reactive Protein Level between chronic kidney disease stage. Biomolecular and Health Science, 1 (1). pp. 1-7. ISSN 2620-8636

	Text (Artikel) Comparison of high-sensitivity c-reactive protein level between chronic kidney disease stages.pdf Download (1MB)
	Text (Peer Review) Comparison of high.pdf Download (1MB)
	Text (Similarity) Comparison of high-sensitivity c-reactive protein level between chronic kidney disease stages.pdf Download (2MB)

Abstract

Aim : This research is to evaluate the hs-CRP level comparison between CKD stages in Dr. Soetomo General Hospital Surabaya. Methods: An analytic observational cross-sectional study, evaluating the differences of hs-CRP level between CKD stages in 72 patients (mean age 55.49±7.62 years, the ratio between male:female was 1:1.48, mean BMI 24.18±3.64 kg/m2, 36.11% diabetics, 43.05% on ACEI/ARB, 29.16% on statin), recruited from Nephrology Outpatient Clinic, Dr Soetomo General Hospital, Surabaya, from January to May 2014. The stages were stratified according to the MDRD formula. Results: The mean hs-CRP of CKD stage 3 was 2.29±2.86, stage 4 was 2.48 ± 2.19, and non-dialysis stage 5 was 2.09 ± 2.54. The analysis using Kruskal-Wallis test showed no significant differences among patients with CKD stage 3, stage 4, and non-dialysis stage 5 (median 1.25 vs 1.80 vs 1.05 mg/L; p=0.430). No significant differences of the serum hs-CRP level were detected between diabetics and non diabetics in stage 3, 4, and non-dialysis stage 5 (p=0.673 vs 0.666 vs 0.138); between patients with and without ACEI/ARB treatment (p=0.610 vs 0.649 vs 0.671); and between patients with and without statin treatment (p=0.852 vs 0.341 vs 0.309). Conclusion: The elevation of serum hs-CRP level can not indicate the decline of kidney function, but it still needs further investigations.

Actions (login required)

View Item